delivering drugs is mostly suitable for lipophilic drugs and poorly water soluble BCS Class II Drugs. It involves dissolving water insoluble drug in non volatile solvents and converting into acceptably ... most…
emulsions when introduced into aqueous phase under mild agitation. After oral delivery of BCS class-II drugs, over one-half of the drug compounds are diminished in the gastrointestinal ... tract. BCS class-II drugs…
Nimesulide, a widely prescribed anti-inflammatory analgesic drug belongs to BCS class II and exhibit low and variable oral bioavailability due to its poor solubility and dissolution rate. The objective ... modified…
response. Poor water solubility of new chemical entities belonging to Biopharmaceutical Classification System (BCS) class II and IV accounts for 40 to 70% incidence of delay or failure during ... overcome their traits…
response. Poor water solubility of new chemical entities belonging to biopharmaceutical classification system (BCS) class II and IV accounts for 40 to 70% incidence of delay or failure during ... meet the aforesaid…
Clofazimine is BCS class II/IV drug with low solubility and high/low permeability which has low bioavailability and high intraand inter subject variability when given orally. In the present
drug (riluzole) has been approved for the treatment of ALS. Riluzole is a BCS class II drug having 60% absolute bioavailability. It is a substrate of P-glycoprotein
Oral extended-release delivery of Biopharmaceutics Classification System (BCS) class II and III compounds is desirable in order to decrease dosing frequency and potential adverse effects. Maintaining an extended-release…
Class II BCS drugs have dissolution and bioavailability challenges. Thus, lipid-based formulations have been explored to address them. Artemether and Lumefantrine investigated in this work are poorly soluble, requiring
Efavirenz widely prescribed anti-retroviral drug belongs to class II BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility and it requires enhancement in solubility ... recommended for…
then used for the preparation of drug-loaded NPs. Different model drugs: ibuprofen (BCS class II), acyclovir (BCS class III) and furosemide (BCS class IV) were incorporated into NPs using
those drugs having poor aqueous solubility. Drugs belonging to Biopharmaceutical Classification System (BCS) class II are characterized by low aqueous solubility and high physiological permeability. Solid Dispersion…
Etoricoxib, a relatively new widely prescribed NSAID drug belongs to class II under BCS and exhibit low and variable bioavailability due to its poor aqueous solubility and needs enhancement ... recommended for enhancing…
emerging as a preferred approach to address challenges involved in the delivery of BCS class-II compounds (poorly soluble and highly permeable).The development of nanoparticle formulations for BCS class
regulatory decisions on bioequivalence. Advancements in solubility enhancement techniques are crucial for BCS Class II and IV drugs. Permeability and dissolution testing are continuously refined to improve predictive…
aqueous solubility (201μg/ml) and high permeability and therefore classified as BCS class II drug. By formulating these drugs with cyclodextrins as inclusion complexes have shown to increase the bioavailability
drug having low solubility due to its crystalline nature. Drug is coming under class II BCS classification. Here it is an attempt to improve solubility by inclusion complexation method
scientific advancements are discussed. The detailed study of the dissolution of poorly absorbed BCS class II drugs in nutritive liquids (such milk and peanut oil) and biorelevant media ... prediction of the rate and…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.